Novartis AG stock (CH0012005267): focus on Sandoz spin-off and pipeline momentum

Novartis AG is reshaping its portfolio after spinning off generics unit Sandoz in 2023 and pushing ahead with a focused innovative-medicines strategy. The stock remains in focus as investors track key drug launches, margin targets and capital returns.

Novartis AG remains in the spotlight for global healthcare investors as the Swiss pharma group continues to execute its focused medicines strategy following the spin-off of Sandoz in October 2023, which turned Novartis into a more pure-play innovative drug company, according to Novartis press release as of 10/04/2023.

As of: 28.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novartis
• Sector/industry: Pharmaceuticals / Healthcare
• Headquarters/country: Switzerland
• Core markets: Global prescription drug market with strong US and European presence
• Key revenue drivers: Innovative branded medicines in oncology, immunology, neuroscience and cardiovascular disease
• Home exchange/listing venue: SIX Swiss Exchange (NVS ADR on NYSE)
• Trading currency: Swiss franc (primary listing)

Novartis AG: core business model

Novartis operates as a global research-driven pharmaceutical group that develops, manufactures and markets patented prescription medicines targeting serious chronic and acute diseases across multiple therapeutic areas, as described in the company’s annual reporting, according to Novartis investor overview as of 02/01/2024.

Following the separation of the Sandoz generics and biosimilars business, Novartis is now primarily focused on higher-margin innovative medicines, which typically benefit from patent protection and require substantial R&D investment over long development cycles, according to Novartis press release as of 09/05/2023.

The group’s business model relies on discovering new molecular entities, advancing them through clinical trials, obtaining regulatory approvals in key markets such as the United States and the European Union, and then commercializing these therapies through its global sales and marketing infrastructure, according to Novartis Annual Report 2023 as of 02/01/2024.

Novartis focuses on selected therapeutic franchises where management sees opportunities for differentiated products and durable competitive advantages, including oncology, cardiovascular-renal-metabolic disorders and neuroscience, according to Novartis strategy update as of 11/30/2023.

The company seeks to enhance shareholder returns through a combination of earnings growth, disciplined capital allocation, recurring dividends and share buybacks within the boundaries of its balance sheet and credit metrics, as outlined in management’s capital markets presentations, according to Novartis Capital Markets Day materials as of 11/30/2023.

Main revenue and product drivers for Novartis AG

Novartis generates revenue mainly from branded prescription medicines sold through its Innovative Medicines segments, with key contributors including oncology therapies such as Kisqali for breast cancer and targeted treatments like Pluvicto and Lutathera, according to Novartis Q4/FY 2023 results as of 01/31/2024.

In cardiovascular and renal medicine, products such as Entresto for heart failure and newer assets in the cardiovascular and metabolic pipeline have been highlighted as growth engines, particularly in the large US market where heart failure and cardiometabolic diseases remain prevalent, according to Novartis media release as of 09/12/2023.

Novartis reported that 2023 net sales from continuing operations grew supported by strong performance of growth brands and new launches, while the company continues to manage the erosion of older, off-patent products, according to Novartis Q4/FY 2023 results as of 01/31/2024.

The pipeline remains an important value driver, with management pointing to late-stage candidates across oncology, immunology and neuroscience that could support medium-term revenue growth if regulatory approvals and market adoption are achieved, according to Novartis pipeline overview as of 03/01/2024.

In addition to internal R&D, Novartis regularly uses business development deals such as licensing agreements and bolt-on acquisitions to complement its portfolio in priority therapeutic areas, as illustrated by multiple transactions highlighted in recent investor materials, according to Novartis investor presentation library as of 03/15/2024.

Conclusion

Novartis AG has transformed into a more focused innovative-medicines company following the Sandoz spin-off, with growth anchored in oncology and cardiovascular-renal-metabolic franchises, according to company disclosures and recent annual reporting, as noted in the sources above.

For US-focused investors, the stock offers exposure to a large global pharmaceutical player with a strong presence in the American prescription drug market and an established track record of late-stage drug development, while still facing the familiar sector challenges of pricing pressure, regulatory scrutiny and patent expiries.

Future performance of Novartis shares will depend on the commercial success of key growth brands, the outcome of pivotal clinical trials in the late-stage pipeline, and the company’s ability to maintain attractive margins and capital returns through economic and regulatory cycles.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.